The authorization permits manufacture at CuraTeq’s facility in Hyderabad and marketing of Bevqolva in 100mg/4ml and 400mg/15ml vial presentations, Aurobindo Pharma said.
On another note, last week, Aurobindo Pharma said the US drug regulator classified its Unit-VII facility in Telangana as ‘voluntary action needed’ (VAI).
The facility manufactures oral solid dosage products. The USFDA had inspected it from January 28 to February 10, 2026, following which it issued a Form 483 with nine observations.Aurobindo Pharma said it received the establishment inspection report (EIR) last week classifying the facility as VAI and said the USFDA had concluded the inspection and closed the matter.
A VAI classification indicates that while objectionable conditions were found during inspection, the regulator does not recommend or undertake administrative or regulatory action at the facility.
Shares of Aurobindo Pharma ended the previous session flat at ₹1,510.3 apiece. The stock has risen 8.9% in the past month and 26.6% this year, so far.
Also Read: AB Capital board to meet on May 20 to consider fund raise proposal via issue of shares, QIP, preferential issue
